Synergistic effects of glutaminase and proteasome inhibition in multiple myeloma cell lines

被引：0
|
作者：
Viswanadha, Srikant [1 ]
Eleswarapu, Satyanarayana [1 ]
Penmetsa, Kumar V. [2 ]
Vakkalanka, Swaroop [2 ]
机构：
[1] Incozen Therapeut Pvt Ltd, Shameerpet Hyderabad, India
[2] Rhizen Pharmaceut, La Chaux De Fonds, Switzerland
来源：
CANCER RESEARCH | 2018年 / 78卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2018-1889
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1889
引用
收藏
页数：2
相关论文
共 50 条
  • [41] EDO-S101, an Alkylating-HDAC-Inhibitor, is Synergistic With Proteasome Inhibition Against Multiple Myeloma Through Activation of Multiple Pathways
    Besse, Lenka
    Kraus, Marianne
    Besse, Andrej
    Bader, Juergen
    Mehrling, Thomas
    Driessen, Christoph
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (01): : E31 - E32
  • [42] Potent inhibition of multiple proteasome subunits by carfilzomib in solid tumor and multiple myeloma patients
    Lee, S. J.
    Woo, T. M.
    Vallone, M.
    Arastu-Kapur, S.
    Chan, E. T.
    Wong, A. F.
    Le, M. H.
    Hannah, A. L.
    Kirk, C. J.
    ANNALS OF ONCOLOGY, 2011, 22 : 23 - 24
  • [43] Proteasome inhibition enhances oncolytic reovirus therapy in multiple myeloma independently of its direct cytotoxic effects
    Dona, Ada Alice
    Tandoh, Theophilus
    Nigam, Lokesh
    Singer, Mahmoud
    Caserta, Enrico
    Murtadha, Mariam
    Zhu, Yinghui
    Moloudizargari, Milad
    Sharma, Preeti
    Napolitano, Ottavio
    Winchester, Janet
    Chowdhury, Arnab
    Pozhitkov, Alex
    Sanchez, James F.
    Vahed, Hawa
    Marcucci, Guido
    Coffey, Matt
    Nuovo, Gerard
    Sborov, Douglas W.
    Pichiorri, Flavia
    Hofmeister, Craig C.
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2025, 18 (01)
  • [44] Proteasome inhibitors for multiple myeloma
    Okazuka, Kiyoshi
    Ishida, Tadao
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2018, 48 (09) : 785 - 792
  • [45] Proteasome Inhibitors in Multiple Myeloma
    Anderson, Kenneth C.
    SEMINARS IN ONCOLOGY, 2009, 36 (02) : S20 - S26
  • [46] PKC δ inhibition induces cell death in thalidomide and dexamethasone resistant multiple myeloma cell lines.
    Bahlis, NJ
    Sawney, R
    Gerson, S
    BLOOD, 2002, 100 (11) : 393A - 393A
  • [47] The combination of the MTOR inhibitor rapamycin and proteasome inhibitor bortezomib is synergistic in vitro in multiple myeloma
    Leleu, X.
    O'Sullivan, G.
    Jia, X.
    Ngo, H.
    Moreau, A. S.
    Roccaro, A.
    Hatjiharisi, F.
    Hideshima, T.
    Anderson, K.
    Ghobrial, I.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (06): : 148 - 149
  • [48] Efficient electroporation of multiple myeloma cell lines
    Steinbrunn, T.
    Chatterjee, M.
    Einsele, H.
    Bargou, R. C.
    Stuehmer, T.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 148 - 148
  • [49] Proteasome inhibitors induce growth inhibition and apoptosis in myeloma cell lines and in human bone marrow myeloma cells irrespective of chromosome 13 deletion
    Ivana Zavrski
    Cord Naujokat
    Kathrin Niemöller
    Christian Jakob
    Ulrike Heider
    Corinna Langelotz
    Claudia Fleissner
    Jan Eucker
    Kurt Possinger
    Orhan Sezer
    Journal of Cancer Research and Clinical Oncology, 2003, 129 : 383 - 391
  • [50] Proteasome inhibitors induce growth inhibition and apoptosis in myeloma cell lines and in human bone marrow myeloma cells irrespective of chromosome 13 deletion
    Zavrski, I
    Naujokat, C
    Niemöller, K
    Jakob, C
    Heider, U
    Langelotz, C
    Fleissner, C
    Eucker, J
    Possinger, K
    Sezer, O
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2003, 129 (07) : 383 - 391
12345